Evidence map›Paper›PMID 30735000›Full record

ArticleStem cells translational medicine2019

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Michael T Schweizer, Hao Wang, Trinity J Bivalacqua, Alan W Partin, Su Jin Lim, Carolyn Chapman, Rehab Abdallah, Oren Levy, Neil A Bhowmick, Jeffrey M Karp and 4 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. The future of affordable cancer immunotherapy.Frontiers in immunology · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Michael T SchweizerDepartment of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-5510-0661
Hao WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Trinity J BivalacquaDepartment of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Alan W PartinDepartment of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Su Jin LimDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carolyn ChapmanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rehab AbdallahDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Oren LevyCenter for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Neil A BhowmickDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jeffrey M KarpCenter for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Angelo De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
John T IsaacsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
W Nathaniel BrennenDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-9807-7433
Samuel R DenmeadeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
Engineered Induction of a Stem Cell Homing ResponseR01HL095722 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KARP, JEFFREY MICHAEL · 2010 to 2018
$3.9M
NCI NIH HHS P50 CA058236NHLBI NIH HHS R01 HL095722
6 · The paper itself

Abstract

Animal models show that systemically administered bone marrow-derived mesenchymal stem cells (MSCs) home to sites of primary and metastatic prostate cancer (PC)-making them candidates to selectively deliver cytotoxic agents. To further assess this potential as a cell-based therapeutic vehicle, a phase I study testing homing of systemically infused allogeneic MSCs preprostatectomy was conducted. The primary objective was to assess safety and feasibility and to determine if MSCs accumulate within primary PC tissue. MSCs were quantified using beads, emulsion, amplification, magnetics digital polymerase chain reaction (limit of detection: ≥0.01% MSCs) to measure allogeneic MSC DNA relative to recipient DNA. MSCs were harvested from healthy donors and expanded ex vivo using standard protocols by the Johns Hopkins Cell Therapy Laboratory. PC patients planning to undergo prostatectomy were eligible for MSC infusion. Enrolled subjects received a single intravenous infusion 4-6 days prior to prostatectomy. The first three subjects received 1 x 10

Indexed as

AdolescentAdultAnimalsHumansMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiddle AgedProstatic NeoplasmsQuality of LifeTransplantation, HomologousYoung AdultCellular therapyChemotaxisClinical trialsMesenchymal stem cells

Identifiers

PMID30735000
PMCPMC6477003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.